

Eylea®, Eylea® HD (aflibercept) Injection

When requesting Eylea®, Eylea® HD (aflibercept), the individual requiring treatment must be diagnosed with one of the following FDA-approved indications or approved off-label compendial uses and meet the specific coverage guidelines for the covered indication.

FDA-Approved Indications

Eylea is indicated for the treatment of patients with:

- Neovascular (wet) age-related macular degeneration (AMD)
- Macular edema following retinal vein occlusion (RVO)
- Diabetic macular edema (DME)
- Diabetic retinopathy (DR)
- Retinopathy of prematurity (ROP)

Eylea HD is indicated for the treatment of patients with:

- Diabetic macular edema (DME)
- Diabetic retinopathy (DR)
- Neovascular (wet) age-related macular degeneration (AMD)

Approved Off-Label Compendial Uses

Eylea

- Other neovascular ophthalmic conditions (e.g., neovascular glaucoma, sickle cell neovascularization, choroidal neovascular conditions)

Coverage Guidelines

Eylea

For all approved indications the individual must meet the following criteria for approval:

- Eylea is administered by or under the supervision of an ophthalmologist

Eylea HD

Diabetic Macular Edema, Diabetic Retinopathy, Neovascular (Wet) Age-Related Macular Degeneration

The individual must meet the following criteria for approval:

- Eylea is administered by or under the supervision of an ophthalmologist

Approval duration (Eylea and Eylea HD): 12 months

Dosing Recommendations

Eylea

Neovascular (Wet) Age-Related Macular Degeneration (AMD)

The recommended dose is 2 mg administered by intravitreal injection every 4 weeks for the first 3 months, followed by 2 mg via intravitreal injection once every 8 weeks.

Macular Edema Following Retinal Vein Occlusion (RVO)

The recommended dose is 2 mg administered by intravitreal injection once every 4 weeks.

Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)

The recommended dose is 2 mg administered by intravitreal injection every 4 weeks for the first 5 injections followed by 2 mg via intravitreal injection once every 8 weeks.

Retinopathy of Prematurity (ROP)

The recommended dose is 0.4mg administered by intravitreal injection. The interval between doses injected into the same eye should be at least 10 days.

Eylea HD

Neovascular (Wet) Age-related Macular Degeneration (AMD)

The recommended dose is 8 mg administered by intravitreal injection every 4 weeks for the first 3 doses, followed by 8 mg via intravitreal injection once every 8 to 16 weeks.

Diabetic Macular Edema

The recommended dose is 8 mg administered by intravitreal injection every 4 weeks for the first 3 doses, followed by 8 mg via intravitreal injection once every 8 to 16 weeks.

Diabetic Retinopathy

The recommended dose is 8 mg administered by intravitreal injection every 4 weeks for first 3 doses, followed by 8 mg via intravitreal injection once every 8 to 12 weeks.

References

1. Eylea® injection [prescribing information]. Tarrytown, NY: Regeneron Pharmaceuticals, Inc.; August 2023.
2. Barakat MR, Kaiser PK. VEGF inhibitors for the treatment of neovascular age-related macular degeneration. *Expert Opin Investig Drugs*. 2009;18(5):637-646.
3. Tolentino M. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. *Surv Ophthalmol*. 2011;56(2):95-113.
4. Kinnunen K, Ylä-Herttuala S. Vascular endothelial growth factors in retinal and choroidal neovascular diseases. *Ann Med*. 2012;44(1):1-17.
5. Horsley MB, Kahook MY. Anti-VEGF therapy for glaucoma. *Curr Opin Ophthalmol*. 2010;21(2):112-117.
6. Eylea® HD intravitreal injection [prescribing information]. Tarrytown, NY: Regeneron; August 2023.